Literature DB >> 19660658

Trophic factors therapy in Parkinson's disease.

Shilpa Ramaswamy1, Katherine E Soderstrom, Jeffrey H Kordower.   

Abstract

Parkinson's disease (PD) is a progressive, neurodegenerative disorder for which there is currently no effective neuroprotective therapy. Patients are typically treated with a combination of drug therapies and/or receive deep brain stimulation to combat behavioral symptoms. The ideal candidate therapy would be the one which prevents neurodegeneration in the brain, thereby halting the progression of debilitating disease symptoms. Neurotrophic factors have been in the forefront of PD research, and clinical trials have been initiated using members of the GDNF family of ligands (GFLs). GFLs have been shown to be trophic to ventral mesencephalic cells, thereby making them good candidates for PD research. This paper examines the use of GDNF and neurturin, two members of the GFL, in both animal models of PD and clinical trials.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19660658      PMCID: PMC3430519          DOI: 10.1016/S0079-6123(09)17514-3

Source DB:  PubMed          Journal:  Prog Brain Res        ISSN: 0079-6123            Impact factor:   2.453


  46 in total

1.  Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.

Authors:  J H Kordower; M E Emborg; J Bloch; S Y Ma; Y Chu; L Leventhal; J McBride; E Y Chen; S Palfi; B Z Roitberg; W D Brown; J E Holden; R Pyzalski; M D Taylor; P Carvey; Z Ling; D Trono; P Hantraye; N Déglon; P Aebischer
Journal:  Science       Date:  2000-10-27       Impact factor: 47.728

2.  Trophic factor distribution predicts functional recovery in parkinsonian monkeys.

Authors:  Don M Gash; Zhiming Zhang; Yi Ai; Richard Grondin; Robert Coffey; Greg A Gerhardt
Journal:  Ann Neurol       Date:  2005-08       Impact factor: 10.422

3.  Localization of GDNF/neurturin receptor (c-ret, GFRalpha-1 and alpha-2) mRNAs in postnatal rat brain: differential regional and temporal expression in hippocampus, cortex and cerebellum.

Authors:  T C Burazin; A L Gundlach
Journal:  Brain Res Mol Brain Res       Date:  1999-11-10

4.  Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector.

Authors:  Biljana Georgievska; Deniz Kirik; Carl Rosenblad; Cecilia Lundberg; Anders Björklund
Journal:  Neuroreport       Date:  2002-01-21       Impact factor: 1.837

5.  Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor.

Authors:  D Kirik; C Rosenblad; A Björklund
Journal:  Eur J Neurosci       Date:  2000-11       Impact factor: 3.386

6.  Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease.

Authors:  L Wang; S Muramatsu; Y Lu; K Ikeguchi; K Fujimoto; T Okada; H Mizukami; Y Hanazono; A Kume; F Urano; H Ichinose; T Nagatsu; I Nakano; K Ozawa
Journal:  Gene Ther       Date:  2002-03       Impact factor: 5.250

7.  Heparin coinfusion during convection-enhanced delivery (CED) increases the distribution of the glial-derived neurotrophic factor (GDNF) ligand family in rat striatum and enhances the pharmacological activity of neurturin.

Authors:  J F Hamilton; P F Morrison; M Y Chen; J Harvey-White; R S Pernaute; H Phillips; E Oldfield; K S Bankiewicz
Journal:  Exp Neurol       Date:  2001-03       Impact factor: 5.330

8.  alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.

Authors:  C Lo Bianco; J-L Ridet; B L Schneider; N Deglon; P Aebischer
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-16       Impact factor: 11.205

9.  Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys.

Authors:  Richard Grondin; Zhiming Zhang; Ai Yi; Wayne A Cass; Navin Maswood; Anders H Andersen; Dennis D Elsberry; Michael C Klein; Greg A Gerhardt; Don M Gash
Journal:  Brain       Date:  2002-10       Impact factor: 13.501

10.  Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.

Authors:  Yoshitsugu Oiwa; Ryo Yoshimura; Kunio Nakai; Toru Itakura
Journal:  Brain Res       Date:  2002-08-30       Impact factor: 3.252

View more
  26 in total

1.  Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson's disease.

Authors:  Kc Biju; Qing Zhou; Guiming Li; Syed Z Imam; James L Roberts; William W Morgan; Robert A Clark; Senlin Li
Journal:  Mol Ther       Date:  2010-06-08       Impact factor: 11.454

2.  Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors.

Authors:  Kiren Ubhi; Edward Rockenstein; Michael Mante; Chandra Inglis; Anthony Adame; Christina Patrick; Kristen Whitney; Eliezer Masliah
Journal:  J Neurosci       Date:  2010-05-05       Impact factor: 6.167

3.  Fluoxetine ameliorates behavioral and neuropathological deficits in a transgenic model mouse of α-synucleinopathy.

Authors:  Kiren Ubhi; Chandra Inglis; Michael Mante; Christina Patrick; Anthony Adame; Brian Spencer; Edward Rockenstein; Verena May; Juergen Winkler; Eliezer Masliah
Journal:  Exp Neurol       Date:  2012-01-16       Impact factor: 5.330

Review 4.  The pharmacology of regenerative medicine.

Authors:  George J Christ; Justin M Saul; Mark E Furth; Karl-Erik Andersson
Journal:  Pharmacol Rev       Date:  2013-07-01       Impact factor: 25.468

Review 5.  Neuropharmacologic Approaches to Restore the Brain's Microenvironment.

Authors:  Weizhe Li; Hsin-I Tong; Santhi Gorantla; Larisa Y Poluektova; Howard E Gendelman; Yuanan Lu
Journal:  J Neuroimmune Pharmacol       Date:  2016-06-28       Impact factor: 4.147

6.  Akt as a victim, villain and potential hero in Parkinson's disease pathophysiology and treatment.

Authors:  Lloyd A Greene; Oren Levy; Cristina Malagelada
Journal:  Cell Mol Neurobiol       Date:  2011-03-10       Impact factor: 5.046

7.  Bone marrow-derived microglia-based neurturin delivery protects against dopaminergic neurodegeneration in a mouse model of Parkinson's disease.

Authors:  K C Biju; Rene A Santacruz; Cang Chen; Qing Zhou; Jiemin Yao; Sara L Rohrabaugh; Robert A Clark; James L Roberts; Kimberley A Phillips; Syed Z Imam; Senlin Li
Journal:  Neurosci Lett       Date:  2013-01-04       Impact factor: 3.046

8.  Evidence for miR-181 involvement in neuroinflammatory responses of astrocytes.

Authors:  Emmette R Hutchison; Elisa M Kawamoto; Dennis D Taub; Ashish Lal; Kotb Abdelmohsen; Yongqing Zhang; William H Wood; Elin Lehrmann; Simonetta Camandola; Kevin G Becker; Myriam Gorospe; Mark P Mattson
Journal:  Glia       Date:  2013-05-07       Impact factor: 7.452

9.  Deficiency of GDNF Receptor GFRα1 in Alzheimer's Neurons Results in Neuronal Death.

Authors:  Yoshihiro Konishi; Li-Bang Yang; Ping He; Kristina Lindholm; Bai Lu; Rena Li; Yong Shen
Journal:  J Neurosci       Date:  2014-09-24       Impact factor: 6.167

10.  TRPV1 on astrocytes rescues nigral dopamine neurons in Parkinson's disease via CNTF.

Authors:  Jin H Nam; Eun S Park; So-Yoon Won; Yu A Lee; Kyoung I Kim; Jae Y Jeong; Jeong Y Baek; Eun J Cho; Minyoung Jin; Young C Chung; Byoung D Lee; Sung Hyun Kim; Eung-Gook Kim; Kyunghee Byun; Bonghee Lee; Dong Ho Woo; C Justin Lee; Sang R Kim; Eugene Bok; Yoon-Seong Kim; Tae-Beom Ahn; Hyuk Wan Ko; Saurav Brahmachari; Olga Pletinkova; Juan C Troconso; Valina L Dawson; Ted M Dawson; Byung K Jin
Journal:  Brain       Date:  2015-10-21       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.